Loading
TriSalus Life Sciences
TriSalus makes catheter devices that push treatments into tumours in the liver and pancreas by controlling pressure and flow in the blood vessels. It is also testing an immune-stimulating drug, nelitolimod, given through those devices, in early trials.
Also called: TriSalus Life Sciences, Inc.TriSalusMedTech Acquisition Corp
Overview
TriSalus Life Sciences, headquartered in Westminster, Colorado, develops what it calls Pressure-Enabled Drug Delivery (PEDD): devices that modulate pressure and flow in blood vessels to overcome intratumoural pressure and improve delivery of therapies to liver and pancreatic tumours. It has two FDA-cleared devices, the TriNav Infusion System for delivery into the liver and the Pancreatic Retrograde Venous Infusion (PRVI) System, and says PEDD has been used in over 18,000 procedures. In 2020 it acquired nelitolimod (SD-101), an investigational TLR9 agonist, which it is testing delivered by PEDD with checkpoint inhibitors in phase 1 trials in uveal melanoma with liver metastases, hepatocellular carcinoma and intrahepatic cholangiocarcinoma, and locally advanced pancreatic adenocarcinoma (NCT04935229, NCT05220722, NCT05607953). Its common stock trades on Nasdaq as TLSI; SEC records show the listed company was formerly MedTech Acquisition Corp, renamed in August 2023.
Headquarters
Westminster, CO, US
Scorecard
All companies#745of 1706 companies, score 3
- phase 1/2 +1
- modalities +2
0 approved, 0 in phase 3, 1 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsPublic
Investors
Type
Devices & RT hardware · NASDAQ: TLSI
Stage
Public
Website
Products
1Phase 1TLR9 agonist (immunotherapy), given through the company's pressure-enabled drug delivery devices
Nelitolimod is an experimental immune-stimulating drug from TriSalus Life Sciences, in phase 1 trials for locally advanced pancreatic cancer and cancers in the liver.
Notes
- Founding year not stated on the pages read.
- OnCo has no TLR9 target record and no technology record for pressure-enabled intravascular delivery, so targets and technologies are empty.
- None of the TriSalus-sponsored nelitolimod trials has an OnCo trial record. Several investigator trials use the TriNav device with Y-90 radioembolisation.
Connected
11Similar pages
- CompanyPilatus Biosciences
Shares Intrahepatic cholangiocarcinoma, Hepatocellular carcinoma.
- CompanyVirogin Biotech
Shares Intrahepatic cholangiocarcinoma, Hepatocellular carcinoma.
- TrialA Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
Shares Uveal melanoma, Hepatocellular carcinoma.
- CompanyAlterome Therapeutics
Shares OrbiMed, Pancreatic ductal adenocarcinoma.
- PersonAndrew X. Zhu
Shares Intrahepatic cholangiocarcinoma, Hepatocellular carcinoma.
- PersonRobin Kate Kelley
Shares Intrahepatic cholangiocarcinoma, Hepatocellular carcinoma.
- TermBAP1 loss
- TargetGNAQ
Shares Uveal melanoma, Hepatocellular carcinoma.
cancers
fronts
drugs
Phase 1TLR9 agonist (immunotherapy), given through the company's pressure-enabled drug delivery devices
companies
trials
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal MelanomaPressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver TumorsPressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
trisaluslifesci.com · 4
orbimed.com · 1
sec.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/